Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07449351
EARLY_PHASE1

Psilocybin Microdosing on Cognition, Mood and Quality of Life

Sponsor: Yale University

View on ClinicalTrials.gov

Summary

This study is being conducted to evaluate how of 30 days of intermittently microdosed psilocybin affects mood, cognition, subjective well-being and structural/functional MRI results compared to a placebo. Investigators hypothesize that compared to placebo, 30 days of intermittently microdosed psilocybin will produce observable changes in mood, cognition, subjective well-being and MRI, in the absence of psychedelic experiences.

Official title: Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study

Key Details

Gender

All

Age Range

21 Years - 40 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2026-04-01

Completion Date

2028-04-01

Last Updated

2026-03-31

Healthy Volunteers

Yes

Interventions

DRUG

Psliocybin

2.0mg powdered psilocybin derived from Psilocybe cubensis mushrooms, in capsules, provided three times weekly for four weeks

DRUG

Placebo

0mg matching capsules, provided three times weekly for four weeks

Locations (1)

Olin Neuropsychiatry Research Center

Hartford, Connecticut, United States